1. Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?

   • Anastasia Geladaris
   • Sebastian Torke
   • Martin S. Weber

   Leading Article Open access 30 September 2022 Pages: 1019 - 1030

   

2. A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review

   • Niloufar Pouyan
   • Zahra Halvaei Khankahdani
   • Roger S. McIntyre

   Systematic Review Open access 12 September 2022 Pages: 1031 - 1047

   

3. Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research

   • Joseph Junior Damba
   • Katie Bodenstein
   • Kyle T. Greenway

   Systematic Review 26 September 2022 Pages: 1049 - 1077

   

4. Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies

   • Adam Strzelczyk
   • Susanne Schubert-Bast

   Review Article Open access 04 October 2022 Pages: 1079 - 1111

   

5. Eslicarbazepine Acetate as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures in Adults: A Prospective Observational Study

   • Yaroslav Winter
   • Katharina Sandner
   • Sergiu Groppa

   Original Research Article Open access 30 September 2022 Pages: 1113 - 1119

   

6. Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab

   • Michael Auer
   • Angelika Bauer
   • Florian Deisenhammer

   Original Research Article 29 September 2022 Pages: 1121 - 1131

   

7. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder

   • Tina Nie
   • Hannah A. Blair

   Adis Drug Evaluation Open access 07 September 2022 Pages: 1133 - 1141